Discovery of Baicalein as a Novel Ubiquitin‐Specific Protease 21 Inhibitor for the Treatment of Hepatocellular Carcinoma
Phytotherapy Research · 2025-09 · 39 (9) · 3935-3951
DOI: 10.1002/ptr.70022 ↗At a glance
Journal article in Phytotherapy Research, published online on 2025-07-17. Written by Huijun Jia and 9 co-authors. Institution: College of Pharmacy, Dalian Medical University, Dalian, China. Major MEDLINE topics: Flavanones, Carcinoma, Hepatocellular, Liver Neoplasms. Cited 8 times so far (Crossref); 46 references. Funded by: National Natural Science Foundation of China, Dalian High-level Talent Innovation Support Program, Liaoning Province Doctoral Research Initiation Fund Project.
Abstract (original language)
Ubiquitin‐specific protease 21 (USP21) is amplified and overexpressed in hepatocellular carcinoma (HCC), correlating with poor prognosis, suggesting USP21 inhibition as a therapeutic strategy. This study aims to identify novel USP21 inhibitors and elucidate their molecular mechanisms in HCC treatment. USP21 inhibitors were identified via structure‐guided drug discovery, enzymatic assays, and bio‐layer interferometry. Functional validation included proliferation, migration, colony formation, and apoptosis assays. USP21‐mediated hypoxia‐inducible factor‐1α (HIF‐1α) regulation was assessed using qRT‐PCR, co‐immunoprecipitation, and deubiquitination assays. In vivo efficacy was evaluated in murine allograft models, with binding modes resolved via molecular dynamics simulations and binding free energy calculations. Screening 4000 natural compounds identified Baicalein and Hypericin as USP21 inhibitors (50% inhibitory concentration: 2.45 and 17.68 μM, respectively). Baicalein suppressed HCC proliferation, colony formation, and migration while inducing apoptosis. Mechanistically, USP21 directly stabilized HIF‐1α via deubiquitination, which Baicalein disrupted by blocking the USP21‐HIF‐1α interaction, promoting HIF‐1α degradation. In vivo, Baicalein inhibited tumor growth and enhanced intratumoral T‐cell infiltration. Structural analyses identified Gln300, His510, and Gly517 as critical residues for USP21‐inhibitor binding. Baicalein emerges as a dual‐functional USP21 inhibitor that destabilizes HIF‐1α and reprograms the tumor immune microenvironment. The Gln300/His510/Gly517 binding motif provides a structural blueprint for advanced USP21‐targeted drug design, establishing USP21 inhibition as a promising therapeutic strategy for HCC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- College of Pharmacy, Dalian Medical University, Dalian, China.
- College of Basic Medical Sciences, Dalian Medical University, Dalian, China.
- School of Pharmaceutical Engineering and Biotechnology, School of Cosmetics, Zhejiang Pharmaceutical University, Ningbo, China.
ORCID profiles: Peng Chu
Funding
- National Natural Science Foundation of China
- Dalian High-level Talent Innovation Support Program
- Liaoning Province Doctoral Research Initiation Fund Project
- Dalian Medical University Youth Talent Cultivation Fund Project
Cite
APA
Jia, H., Zhao, Z., Su, C., Du, J., Yang, S., Song, J., Han, X., Yu, F., Sun, Z., & Chu, P. (2025). Discovery of Baicalein as a Novel Ubiquitin‐Specific Protease 21 Inhibitor for the Treatment of Hepatocellular Carcinoma. Phytotherapy Research, 39(9), 3935-3951. https://doi.org/10.1002/ptr.70022
Vancouver
Jia H, Zhao Z, Su C, Du J, Yang S, Song J, et al. Discovery of Baicalein as a Novel Ubiquitin‐Specific Protease 21 Inhibitor for the Treatment of Hepatocellular Carcinoma. Phytotherapy Research. 2025;39(9):3935-3951. doi:10.1002/ptr.70022
BibTeX
@article{Jia2025,
author = {Jia, Huijun and Zhao, Zhuoyue and Su, Chen and Du, Jiapeng and Yang, Shuaizhou and Song, Jiankun and Han, Xu and Yu, Fang and Sun, Zhaolin and Chu, Peng},
title = {Discovery of Baicalein as a Novel Ubiquitin‐Specific Protease 21 Inhibitor for the Treatment of Hepatocellular Carcinoma},
journal = {Phytotherapy Research},
year = {2025},
volume = {39},
number = {9},
pages = {3935--3951},
doi = {10.1002/ptr.70022}
}
EUVIMED